MétaCan
Menu
Back to cohort
Record W4400193013 · doi:10.1136/gutjnl-2024-bsg.202

P120 Upadacitinib for moderate-to-severe ulcerative colitis: interim results from U-ACTIVATE phase III open-label extension

2024· article· en· W4400193013 on OpenAlexaff
Remo Panaccione, Peter Higgins, Gary R. Lichtenstein, Hiroshi Nakase, Michelle Kujawski, Erica Cheng, Dapo Ilo, Gweneth Levy, Jason Eccleston, Sarah C. Glover, Silvio Danese, Jean‐Frédéric Colombel, Stefan Schreiber, Ali Terai

Bibliographic record

VenuePoster presentations · 2024
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsOpen labelUlcerative colitisInterimMedicineExtension (predicate logic)Internal medicineComputer scienceClinical trial

Abstract

fetched live from OpenAlex

<h3>Introduction</h3> Upadacitinib (15 mg [UPA15] or 30 mg [UPA30] once daily) demonstrated efficacy vs placebo after 52 weeks (wks) of maintenance therapy in the U-ACHIEVE Maintenance study.<sup>1 2</sup> <h3>Methods</h3> This interim analysis presents efficacy and safety data from patients (pts) receiving UPA15 or UPA30 for an additional 48 wks (~2 years total) in the ongoing, 288-wk, long-term extension (LTE) study U-ACTIVATE. Pts with dose adjustments at wk 48 of the LTE study were excluded from this analysis. Safety during U-ACTIVATE was assessed throughout. <h3>Results</h3> U-ACTIVATE interim analysis included 101 pts in UPA15 arm and 137 pts in UPA30 arm. At wk 48, clinical remission per adapted Mayo Score (aMS) was similar for UPA15 and UPA30 (78.2% [68/87] and 77.3% [92/19], respectively), as was clinical remission per partial Mayo Score (pMS) (92.4% [85/92] and 90.9% [110/121], respectively) and clinical response per aMS (97.7% [85/87] and 95.8% [114/119], respectively). Endoscopic endpoints were also similar between the groups, with maintenance of endoscopic remission numerically higher in UPA30 (81.1%, 43/53) vs UPA15 (71.8%, 28/39). The 238 pts included in the safety analysis achieved 426.5 pt-years (PYs) of exposure (UPA15, 186.0; UPA30, 240.5). Exposure-adjusted event rates (EAERs) of serious treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation were similar in both groups. No deaths occurred in either group. The EAERs for TEAEs of special interest were generally lower with UPA15 vs UPA30, including for serious infections, herpes zoster, neutropenia and creatine phosphokinase elevation. EAER for hepatic disorder was higher with UPA15 vs UPA30 (8.6 vs 4.2 Events/100PY, respectively). No adjudicated major adverse cardiovascular events occurred; no adjudicated venous thromboembolic events occurred with UPA15 and one with UPA30. One event of malignancy excluding non-melanoma skin cancer occurred in both UPA15 and UPA30. <h3>Conclusions</h3> Achievement of clinical and endoscopic endpoints observed with UPA15 and UPA30 after the 52-wk maintenance study<sup>1,2</sup> was sustained through wk 48 of the LTE study. The safety profile of UPA was consistent with previous analyses. <h3>References</h3> Danese S, <i>et al. Lancet</i> 2022;<b>399</b>:2113–28. Vermeire S, <i>et al.</i> Presented at UEGW [OP001], 8–11 October 2022.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.084
Threshold uncertainty score0.826

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.376
Teacher spread0.318 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venuePoster presentationsSame topicInflammatory Bowel DiseaseFrench-language works237,207